Amgen's cholesterol-lowering antibody Repatha is being launched in Europe at well below the new drug's cost in the US, raising the chance that American payers will seek hefty discounts on the drug.
Oxford BioTherapeutics has lined up another big pharma partner for its drug discovery platform, signing a $1bn deal with oncology giant Roche.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback